Encompass Health Corp.: Q1 FY2026 earnings call

What management said about Q1 FY2026, from the documents filed with the SEC on 30 April 2026: press release. Guidance figures: 4 raised, 1 kept. The quarter’s numbers.

Key takeaways

Revenue and earnings rose: Net operating revenue was $1,586.6 million, against $1,455.4 million. Income from continuing operations per diluted share was $1.77, against $1.48, and adjusted EPS was $1.60, against $1.37. Source
Adjusted EBITDA reached $348.8 million: Adjusted EBITDA was $348.8 million, against $313.6 million a year earlier. Adjusted free cash flow is reported separately as a non-GAAP measure. Source
New Irmo hospital opened: The company opened a 49-bed hospital in Irmo, South Carolina, and added 44 beds across existing facilities during the quarter, as part of expanding treatment capacity. Source
Discharges rose; same-store growth 1.6%: Discharges were 67,763, against 64,985 a year earlier, a rise of 4.3%. Same-store discharge growth was 1.6% for the quarter. Source
Operating cash flow rose: Net cash provided by operating activities was $313.1 million, against $288.6 million. Adjusted free cash flow was $193.8 million, against $222.4 million. Source
Distributions to noncontrolling interests rose: Distributions paid to noncontrolling interests of consolidated affiliates were $57.8 million, against $32.9 million. The company cited these distributions in its adjusted free cash flow reconciliation. Source

“We are very pleased with our start to 2026 as first quarter revenue increased 9.0% and Adjusted EBITDA grew 11.2%,”
Mark Tarr, President and Chief Executive Officer

Guidance

Area	Period	Figure	Against last quarter
Net operating revenue Source	full-year 2026	$6,375 to $6,470 million	Raised from $6,365 to $6,465 million
Adjusted EBITDA Source	full-year 2026	$1,350 to $1,380 million	Raised from $1,340 to $1,380 million
Adjusted earnings per share from continuing operations Source	full-year 2026	$5.89 to $6.11	Raised from $5.81 to $6.10
Interest expense and amortization of debt discounts and fees Source	full-year 2026	approximately $125 million	Raised from approximately $120 million
Amortization of debt-related items Source	full-year 2026	approximately $10 million	Kept
New hospitals and beds Source	full-year 2026	eight hospitals with a total of 389 beds

What changed from last quarter

Guidance raised: The company increased full-year 2026 guidance for net operating revenue, from $6,365 to $6,465 million to $6,375 to $6,470 million. Source
Guidance raised: Full-year 2026 Adjusted EBITDA guidance moved from $1,340 to $1,380 million to $1,350 to $1,380 million. The low end was raised. Source
Guidance raised: Full-year 2026 adjusted EPS from continuing operations guidance moved from $5.81 to $6.10 to $5.89 to $6.11. Source
Guidance raised: The estimate for 2026 interest expense and amortization of debt discounts and fees rose from about $120 million to about $125 million. Source
New: The company opened a new 49-bed hospital in Irmo, South Carolina, during the quarter. Source
New: The company recorded a $17.5 million gain on the sale of its Gamma Knife business in the quarter. Source

Results and growth drivers

Revenue and earnings rose: Net operating revenue was $1,586.6 million, against $1,455.4 million. Income from continuing operations per diluted share was $1.77, against $1.48, and adjusted EPS was $1.60, against $1.37. Source
Net income attributable to Encompass Health: Net income attributable to Encompass Health was $194.5 million, against $151.5 million. Discontinued operations contributed $15.9 million, net of tax, within that total. Source
Adjusted EBITDA reached $348.8 million: Adjusted EBITDA was $348.8 million, against $313.6 million a year earlier. Adjusted free cash flow is reported separately as a non-GAAP measure. Source

Capacity and facilities

New Irmo hospital opened: The company opened a 49-bed hospital in Irmo, South Carolina, and added 44 beds across existing facilities during the quarter, as part of expanding treatment capacity. Source
Hospital count rose to 174: The company's footprint is described as 174 hospitals in 39 states and Puerto Rico. The prior release described 173 hospitals in the same states. Source

“Our value proposition and operating strategy continue to be validated and we remain highly optimistic about the long-term prospects of our business.”
Mark Tarr, President and Chief Executive Officer

Patient volumes and pricing

Discharges rose; same-store growth 1.6%: Discharges were 67,763, against 64,985 a year earlier, a rise of 4.3%. Same-store discharge growth was 1.6% for the quarter. Source
Revenue per discharge rose: Net patient revenue per discharge was $22,633, against $21,816 a year earlier, an increase of 3.7%. Source

Costs and income tax

Salaries and benefits rose: Salaries and benefits were $818.1 million, against $762.3 million. Other operating expenses were $241.9 million, against $217.5 million. Source
Depreciation and amortization rose: Depreciation and amortization was $87.3 million, against $79.2 million. Total operating expenses were $1,285.0 million, against $1,188.4 million. Source
Income tax expense rose: The provision for income tax expense was $56.4 million, against $41.6 million, and income from continuing operations was $232.3 million, against $197.0 million. Source

Cash flow and capital spending

Operating cash flow rose: Net cash provided by operating activities was $313.1 million, against $288.6 million. Adjusted free cash flow was $193.8 million, against $222.4 million. Source
Distributions to noncontrolling interests rose: Distributions paid to noncontrolling interests of consolidated affiliates were $57.8 million, against $32.9 million. The company cited these distributions in its adjusted free cash flow reconciliation. Source
Capital spending was little changed: Purchases of property, equipment, and intangible assets were $162.4 million, against $163.1 million. Net cash used in investing activities was $150.1 million, mainly capital expenditures. Source

Shareholder cash returns

Share repurchases rose: Repurchases of common stock, including fees and expenses, were $71.6 million, against $32.1 million a year earlier. Source
Dividends paid rose: Dividends paid on common stock were $20.3 million, against $18.0 million a year earlier. Source
Diluted share count declined: Diluted weighted average common shares were 100.6 million, against 102.1 million a year earlier. Source

Debt, asset sale and balance sheet

Long-term debt increased: Long-term debt, net of current portion, was $2,530.9 million at March 31, 2026, against $2,447.2 million at December 31, 2025. Source
Revolver borrowings exceeded repayments: The company borrowed $420.0 million on its revolving credit facility and paid back $330.0 million during the quarter. Source
Gamma Knife sale gain recorded: The company recorded a $17.5 million gain on the sale of Gamma Knife. The gain is removed in reconciling net income to Adjusted EBITDA. Source

Coming up, as management said on 30 April 2026

Form 10-Q to be filed: The company's Form 10-Q for the quarter ended March 31, 2026 is to be filed later and is to be read alongside this release. Source

Figures management reported

Figure	Reported
Discharges (patient volumes) Source	67,763 in Q1 2026, against 64,985 in Q1 2025 (up 4.3%)
Same-store discharge growth (utilization) Source	1.6%
Net patient revenue per discharge Source	$22,633 in Q1 2026, against $21,816 in Q1 2025 (up 3.7%)

Risks management discussed

Financial: Management said certain items outside its control, such as settlements and other non-operating items, cannot be predicted and could be material to GAAP results. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.

As filed with the SEC

Open the filing on EDGAR

Encompass Health reports results for first quarter 2026

Increases full-year guidance

BIRMINGHAM, Ala. - Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the first quarter ended March 31, 2026.

Summary results

					Growth
	Q1 2026		Q1 2025		Dollars	Percent
	(In Millions, Except Per Share Data)
Net operating revenue	$1,586.6		$1,455.4		$131.2	9.0%
Income from continuing operations attributable to Encompass Health per diluted share	1.77		1.48		0.29	19.6%
Adjusted earnings per share	1.60		1.37		0.23	16.8%
Cash flows provided by operating activities	313.1		288.6		24.5	8.5%
Adjusted EBITDA	348.8		313.6		35.2	11.2%
Adjusted free cash flow	193.8		222.4		(28.6)	(12.9)%
(Actual Amounts)
Discharges		67,763		64,985		4.3%
Same-store discharge growth						1.6%
Net patient revenue per discharge	$22,633		$21,816			3.7%

See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.

“We are very pleased with our start to 2026 as first quarter revenue increased 9.0% and Adjusted EBITDA grew 11.2%,” said Mark Tarr, President and Chief Executive Officer. “During the quarter, we continued to expand our capacity to treat patients in need of inpatient rehabilitation services, opening a new 49-bed hospital in Irmo, South Carolina, and adding 44 beds across existing facilities. For the full-year 2026, we expect to open eight hospitals with a total of 389 beds and add approximately 175 beds to existing hospitals. Our value proposition and operating strategy continue to be validated and we remain highly optimistic about the long-term prospects of our business.”

2026 Guidance

The Company increased its full-year guidance as follows:

	Full-Year 2026 Guidance
	Previous Guidance	Updated Guidance
	(In Millions, Except Per Share Data)
Net operating revenue	$6,365 to $6,465	$6,375 to $6,470
Adjusted EBITDA	$1,340 to $1,380	$1,350 to $1,380
Adjusted earnings per share from continuing operations attributable to Encompass Health	$5.81 to $6.10	$5.89 to $6.11

For considerations regarding the Company’s 2026 guidance, see the supplemental information posted on the Company’s website at http://investor.encompasshealth.com. See also the “Other information” section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.

Earnings conference call and webcast

The Company will host an investor conference call at 10:00 a.m. Eastern Time on Friday, May 1, 2026 to discuss its results for the first quarter of 2026. For reference during the call, the Company will post certain supplemental information at http://investor.encompasshealth.com.

The conference call may be accessed by dialing 800 267-6316 and giving the conference ID EHCQ126. International callers should dial 203 518-9783 and give the same conference ID. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at http://investor.encompasshealth.com by clicking on an available link.

About Encompass Health

Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 174 hospitals in 39 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is recognized as America’s Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista and is ranked among Fortune's World’s Most Admired Companies™ and Forbes’ America’s Best Companies. For more information, visit encompasshealth.com, or follow us on our newsroom, X, Instagram and Facebook.

From Fortune. © 2026 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World’s Most Admired Companies™ is trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health.

Other information

The information in this press release is summarized and should be read in conjunction with the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the “March 2026 Form 10-Q”), when filed, as well as the Company’s Current Report on Form 8-K filed on April 30, 2026 (the “Q1 Earnings Form 8-K”), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at http://investor.encompasshealth.com for reference during its May 1, 2026 earnings call.

The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q1 Earnings Form 8-K. Readers are encouraged to review the “Note Regarding Presentation of Non-GAAP Financial Measures” included in the Q1 Earnings Form 8-K which provides further explanation and disclosure regarding the Company’s use of these non-GAAP financial measures.

Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees - accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company’s results computed in accordance with GAAP.

However, the following reasonably estimable GAAP measures for 2026 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:

Interest expense and amortization of debt discounts and fees - approximately $125 million
Amortization of debt-related items - approximately $10 million

The Q1 Earnings Form 8-K and, when filed, the March 2026 Form 10-Q can be found on the Company’s website at http://investor.encompasshealth.com and the SEC's website at www.sec.gov.

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

	Three Months Ended March 31,
	2026		2025
	(In Millions, Except Per Share Data)
Net operating revenues	$1,586.6		$1,455.4
Operating expenses:
Salaries and benefits	818.1		762.3
Other operating expenses	241.9		217.5
Occupancy costs	15.2		14.9
Supplies	64.3		62.2
General and administrative expenses	58.2		52.3
Depreciation and amortization	87.3		79.2
Total operating expenses	1,285.0		1,188.4
Loss on early extinguishment of debt	0.2		-
Interest expense and amortization of debt discounts and fees	31.8		31.8
Other income	(18.7)		(2.5)
Equity in net income of nonconsolidated affiliates	(0.4)		(0.9)
Income from continuing operations before income tax expense	288.7		238.6
Provision for income tax expense	56.4		41.6
Income from continuing operations	232.3		197.0
Income (loss) from discontinued operations, net of tax	15.9		(0.5)
Net income	248.2		196.5
Less: Net income attributable to noncontrolling interests	(53.7)		(45.0)
Net income attributable to Encompass Health	$194.5		$151.5
Weighted average common shares outstanding:
Basic		99.2		100.5
Diluted		100.6		102.1
Earnings per common share:
Basic earnings per share attributable to Encompass Health common shareholders:
Continuing operations	$1.80		$1.50
Discontinued operations	0.16		-
Net income	$1.96		$1.50
Diluted earnings per share attributable to Encompass Health common shareholders:
Continuing operations	$1.77		$1.48
Discontinued operations	0.16		-
Net income	$1.93		$1.48
Amounts attributable to Encompass Health common shareholders:
Income from continuing operations	$178.6		$152.0
Income (loss) from discontinued operations, net of tax	15.9		(0.5)
Net income attributable to Encompass Health	$194.5		$151.5

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

(Unaudited)

	March 31, 2026	December 31, 2025
	(In Millions)
Assets
Current assets:
Cash and cash equivalents	$110.5	$72.2
Restricted cash	52.9	30.7
Accounts receivable	676.0	619.2
Other current assets	189.7	183.8
Total current assets	1,029.1	905.9
Property and equipment, net	4,216.5	4,101.6
Operating lease right-of-use assets	205.3	212.6
Goodwill	1,317.6	1,317.6
Intangible assets, net	300.3	308.3
Other long-term assets	244.4	243.7
Total assets	$7,313.2	$7,089.7
Liabilities and Shareholders’ Equity
Current liabilities:
Current portion of long-term debt	$42.9	$43.6
Current operating lease liabilities	26.9	26.5
Accounts payable	204.0	178.2
Accrued expenses and other current liabilities	603.0	588.1
Total current liabilities	876.8	836.4
Long-term debt, net of current portion	2,530.9	2,447.2
Long-term operating lease liabilities	188.7	196.6
Deferred income tax liabilities	135.1	126.8
Other long-term liabilities	214.5	206.9
Total liabilities	3,946.0	3,813.9
Commitments and contingencies
Redeemable noncontrolling interests	58.8	58.3
Shareholders’ equity:
Encompass Health shareholders’ equity	2,521.7	2,438.2
Noncontrolling interests	786.7	779.3
Total shareholders’ equity	3,308.4	3,217.5
Total liabilities and shareholders’ equity	$7,313.2	$7,089.7

Encompass Health Corporation and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	Three Months Ended March 31,
	2026	2025
	(In Millions)
Cash flows from operating activities:
Net income	$248.2	$196.5
(Income) loss from discontinued operations, net of tax	(15.9)	0.5
Adjustments to reconcile net income to net cash provided by operating activities -
Depreciation and amortization	87.3	79.2
Stock-based compensation	11.5	9.5
Deferred tax expense	8.5	8.8
(Gain) loss on investments	(16.2)	0.1
Other, net	2.3	2.2
Change in assets and liabilities, net of acquisitions -
Accounts receivable	(53.2)	(24.7)
Other assets	(11.6)	0.7
Accounts payable	(2.0)	(2.1)
Other liabilities	33.0	18.6
Net cash provided by (used in) operating activities of discontinued operations	21.2	(0.7)
Total adjustments	80.8	91.6
Net cash provided by operating activities	313.1	288.6
Cash flows from investing activities:
Purchases of property, equipment, and intangible assets	(162.4)	(163.1)
Proceeds from sale of restricted investments	42.9	11.0
Purchases of restricted investments	(26.4)	(2.3)
Other, net	(4.2)	(4.1)
Net cash used in investing activities	(150.1)	(158.5)
Cash flows from financing activities:
Borrowings on revolving credit facility	420.0	60.0
Payments on revolving credit facility	(330.0)	(80.0)
Repurchases of common stock, including fees and expenses	(71.6)	(32.1)
Dividends paid on common stock	(20.3)	(18.0)
Distributions paid to noncontrolling interests of consolidated affiliates	(57.8)	(32.9)
Taxes paid on behalf of employees for shares withheld	(30.9)	(19.8)
Other, net	(11.9)	(7.6)
Net cash used in financing activities	(102.5)	(130.4)
Increase (decrease) in cash, cash equivalents, and restriced cash	60.5	(0.3)
Cash, cash equivalents, and restricted cash at beginning of period	102.9	123.1
Cash, cash equivalents, and restricted cash at end of period	$163.4	$122.8

Encompass Health Corporation and Subsidiaries

Supplemental Information

Earnings Per Share

	Three Months Ended March 31,
	2026		2025
	(In Millions, Except Per Share Data)
Adjusted EBITDA	$348.8		$313.6
Depreciation and amortization	(87.3)		(79.2)
Interest expense and amortization of debt discounts and fees	(31.8)		(31.8)
Stock-based compensation	(11.5)		(9.5)
Loss on disposal or impairment of assets	(0.3)		(0.2)
	217.9		192.9
Items not indicative of ongoing operating performance:
Loss on early extinguishment of debt	(0.2)		-
Change in fair market value of marketable securities	(0.2)		0.7
Gain on sale of Gamma Knife	17.5		-
Pre-tax income	235.0		193.6
Income tax expense	(56.4)		(41.6)
Income from continuing operations	$178.6		$152.0
Basic shares		99.2		100.5
Diluted shares		100.6		102.1
Basic earnings per share	$1.80		$1.50
Diluted earnings per share	$1.77		$1.48

Income from continuing operations attributable to Encompass Health

Encompass Health Corporation and Subsidiaries

Supplemental Information

Adjusted Earnings Per Share

	Three Months Ended March 31,
	2026	2025
Earnings per share, as reported	$1.77	$1.48
Adjustments, net of tax:
Income tax adjustments	(0.05)	(0.12)
Gain on sale of Gamma Knife	(0.13)	-
Adjusted earnings per share*	$1.60	$1.37

* Adjusted EPS may not sum due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

	Three Months Ended March 31,
	2026	2025
	(In Millions)
Net cash provided by operating activities	$313.1	$288.6
Interest expense and amortization of debt discounts and fees	31.8	31.8
Gain (loss) on investments, excluding impairments	16.2	(0.1)
Equity in net income of nonconsolidated affiliates	0.4	0.9
Net income attributable to noncontrolling interests in continuing operations	(53.7)	(45.0)
Amortization of debt-related items	(2.4)	(2.4)
Distributions from nonconsolidated affiliates	(0.1)	(0.5)
Current portion of income tax expense	47.9	32.8
Change in assets and liabilities	33.8	7.5
Cash (provided by) used in operating activities of discontinued operations	(21.2)	0.7
Change in fair market value of marketable securities	0.2	(0.7)
Gain on sale of Gamma Knife	(17.5)	-
Other	0.3	-
Adjusted EBITDA	$348.8	$313.6

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share

	For the Three Months Ended March 31, 2026
			Adjustments
	As Reported		Loss on Early Exting. of Debt	Income Tax Adjustments	Change in Fair Market Value of Marketable Securities	Gain on Sale of Gamma Knife	As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$348.8		$ -	$ -	$ -	$ -	$348.8
Depreciation and amortization	(87.3)		-	-	-	-	(87.3)
Interest expense and amortization of debt discounts and fees	(31.8)		-	-	-	-	(31.8)
Stock-based compensation	(11.5)		-	-	-	-	(11.5)
Loss on disposal or impairment of assets	(0.3)		-	-	-	-	(0.3)
Loss on early extinguishment of debt	(0.2)		0.2	-	-	-	-
Change in fair market value of marketable securities	(0.2)		-	-	0.2	-	-
Gain on sale of Gamma Knife	17.5		-	-	-	(17.5)	-
Income from continuing operations before income tax expense	235.0		0.2	-	0.2	(17.5)	217.9
Provision for income tax expense	(56.4)		(0.1)	(4.7)	-	4.5	(56.7)
Income from continuing operations attributable to Encompass Health	$178.6		$0.1	$(4.7)	$0.2	$(13.0)	$161.2
Diluted earnings per share from continuing operations**	$1.77		$ -	$(0.05)	$ -	$(0.13)	$1.60
Diluted shares used in calculation		100.6

* Reconciliation to GAAP provided on page 9

** Adjusted EPS may not sum across due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share

	For the Three Months Ended March 31, 2025
			Adjustments
	As Reported		Income Tax Adjustments	Change in Fair Market Value of Marketable Securities	As Adjusted
	(In Millions, Except Per Share Amounts)
Adjusted EBITDA*	$313.6		$ -	$ -	$313.6
Depreciation and amortization	(79.2)		-	-	(79.2)
Interest expense and amortization of debt discounts and fees	(31.8)		-	-	(31.8)
Stock-based compensation	(9.5)		-	-	(9.5)
Loss on disposal or impairment of assets	(0.2)		-	-	(0.2)
Change in fair market value of marketable securities	0.7		-	(0.7)	-
Income from continuing operations before income tax expense	193.6		-	(0.7)	192.9
Provision for income tax expense	(41.6)		(12.0)	0.2	(53.4)
Income from continuing operations attributable to Encompass Health	$152.0		$(12.0)	$(0.5)	$139.5
Diluted earnings per share from continuing operations**	$1.48		$(0.12)	$ -	$1.37
Diluted shares used in calculation		102.1

* Reconciliation to GAAP provided on page 9

** Adjusted EPS may not sum across due to rounding.

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Income to Adjusted EBITDA

	Three Months Ended March 31,
	2026	2025
	(In Millions)
Net income	$248.2	$196.5
(Income) loss from discontinued operations, net of tax, attributable to Encompass Health	(15.9)	0.5
Net income attributable to noncontrolling interests included in continuing operations	(53.7)	(45.0)
Provision for income tax expense	56.4	41.6
Interest expense and amortization of debt discounts and fees	31.8	31.8
Depreciation and amortization	87.3	79.2
Loss on early extinguishment of debt	0.2	-
Loss on disposal or impairment of assets	0.3	0.2
Stock-based compensation	11.5	9.5
Change in fair market value of marketable securities	0.2	(0.7)
Gain on sale of Gamma Knife	(17.5)	-
Adjusted EBITDA	$348.8	$313.6

Encompass Health Corporation and Subsidiaries

Supplemental Information

Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow

	Three Months Ended March 31,
	2026	2025
	(In Millions)
Net cash provided by operating activities	$313.1	$288.6
Impact of discontinued operations	(21.2)	0.7
Net cash provided by operating activities of continuing operations	291.9	289.3
Capital expenditures for maintenance	(43.8)	(34.0)
Distributions paid to noncontrolling interests of consolidated affiliates	(57.8)	(32.9)
Items not indicative of ongoing operating performance:
Transaction costs and related liabilities	3.5	-
Adjusted free cash flow	$193.8	$222.4

For the three months ended March 31, 2026, net cash used in investing activities was $150.1 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended March 31, 2026 was $102.5 million and resulted primarily from repurchases of common stock, distributions paid to noncontrolling interests of consolidated affiliates, and taxes paid on behalf of employees for shares withheld partially offset by net debt borrowings.

For the three months ended March 31, 2025, net cash used in investing activities was $158.5 million and resulted primarily from capital expenditures. Net cash used in financing activities during the three months ended March 31, 2025 was $130.4 million and resulted primarily from distributions paid to noncontrolling interests of consolidated affiliates, repurchases of common stock, net debt payments, and cash dividends paid on common stock.

Encompass Health Corporation and Subsidiaries

Forward-Looking Statements

Forward-looking statements notice

Statements contained in this press release and the supplemental information which are not historical facts, such as those relating to the business, strategy, outlook, growth targets and guidance considerations, dividend strategies, effective income tax rates, cost trends, legislative and regulatory developments or their impacts, financial guidance, ability to return value to shareholders, projected capital expenditures, acquisition opportunities, development projects, addressable market size, other balance sheet and cash flow plans, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, Encompass Health, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Encompass Health undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Encompass Health include, but are not limited to, possible reductions or other changes in Medicaid, including Medicaid directed and supplemental payment programs and Medicaid waiver programs, which may decrease our revenues and increase our provider tax expenses; infectious disease outbreak, including the speed, depth, geographic reach and duration of its spread, which could decrease our patient volumes and revenues and lead to staffing and supply shortages and associated cost increases; Encompass Health's infectious disease prevention and control efforts; the demand for Encompass Health’s services, including based on any downturns in the economy and consumer confidence in patient care; the price of Encompass Health's common stock as it affects Encompass Health's willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving Encompass Health, including any matters related to yet undiscovered issues, if any, in acquired operations; Encompass Health's ability to attract and retain key management personnel; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of Encompass Health's or its vendors' or partners’ information systems, including unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability; Encompass Health's ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; increases in Medicare audit activity, including increased use of sampling and extrapolation, resulting in additional unpaid reimbursement claims and an increase in the backlog of appealed claims denials; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for Encompass Health's services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction and Encompass Health's ability to adapt operations to those changes, including in connection with the CMS inpatient rehabilitation review choice demonstration project; competitive pressures in the healthcare industry and Encompass Health's response thereto; Encompass Health's ability to obtain and retain favorable arrangements with third-party payors; Encompass Health's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in Encompass Health's ability to recover improperly denied claims through the administrative appeals process on a timely basis, including as part of the review choice demonstration; Encompass Health's ability to adapt to changes in the healthcare delivery system, including value-based purchasing such as the transforming episode accountability model and involvement in coordinated care initiatives or programs that may arise with its referral sources; Encompass Health's ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages, which may be worsened by infectious disease outbreaks, and the impact on Encompass Health's labor expenses from potential union activity, staffing shortages, and competitive compensation practices; general conditions in the economy and capital markets, including any instability or uncertainty related to trade war, armed conflict or an act of terrorism, governmental impasse over approval of the United States federal budget, an increase in the debt ceiling, or an international sovereign debt crisis; the increase in

Encompass Health Corporation and Subsidiaries

Forward-Looking Statements

the cost of, or the decrease in the availability of, construction materials and necessary supplies, including as a result of tariffs and import restrictions; the increase in the costs of defending and insuring against alleged professional liability claims, and Encompass Health's ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in Encompass Health's SEC filings and other public announcements, including Encompass Health's Form 10‑K for the year ended December 31, 2025 and Form 10-Q for the quarter ended March 31, 2026, when filed.

Contacts
Polly Manuel, 205 969-4532 · polly.manuel@encompasshealth.com · Investor Relations Contact · Mark Miller, 205 970-5860 · mark.miller@encompasshealth.com
April 30, 2026